Search

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more [...]

DUBLIN, March 11, 2024 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5942096/cell-cryopreservation-market-forecasts?utm_source=CI&utm_medium=PressRelease&utm_code=wt3r52&utm_campaign=1943957+-+Cell+Cryopreservation+Market+Report+2024-2029%2c+with+Profiles+of+Key+Players+Irvine+Scientific%2c+Biogenuix%2c+Cryo-Cell%2c+Sartorius%2c+Sigma-Aldrich%2c+Cytiva%2c+AMSBIO+and+Transgen+Biotech&utm_exec=carimspi report has been added toResearchAndMarkets.com's offering. The cell cryopreservation market is estimated to grow at a CAGR of 22.35% during the forecast [...]

2023 DEC 31 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levels No neurotoxicity or dose-limiting toxicities observed Two out of nine patients showed early response on [...]

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumours, reports on 24 Apr 2023 final Phase I dose escalation results from first-in-human Study of HLA-A 02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy (MDG1011) for high-risk myeloid and lymphoid neoplasms (NCT03503968). The data will be presented as an eposter (P227) at the European Society for Blood and Marrow Transplantation (EBMT) 2023 annual meeting, being held 23-26 Apr 2023, in Paris. MDG1011 is an autologous TCR-T therapy specific for a peptide fragment of PRAME (PReferentially expressed Antigen in MElanoma), a tumour antigen presented on cancer cells by human leukocyte antigen HLA-A 02:01. In the open-label, first-in-human Phase I study conducted at nine clinical centres throughout Germany, thirteen patients (ten with acute myeloid leukaemia (AML), two with multiple myeloma (MM) and one with myelodysplastic syndrome and myeloproliferative neoplasm MDS/MPN)) underwent leukapheresis for TCR-T cell manufacture, with four patients succumbing to disease prior to treatment. Subsequently, nine patients with relapsed or refractory AML, MDS/MPN or MM received MDG1011 by single intravenous infusion after a lymphodepleting regimen. Patients received MDG1011 at one of three escalating dose levels (DL): 0.1 (DL1), 1.0 (DL2) or 5.0 (DL3) million TCR-transduced T cells per kg body weight. Immune monitoring of patients included quantification of PRAME levels in bone marrow (BM) and/or peripheral blood (PB) and pharmacokinetics of MDG1011 in PB. Clinical and biological data analysis: Of the 124 adverse events (AEs), 54 were more than Grade 3 toxicities: 31 related to lymphodepletion and 21 related to the investigational medicinal product. Severe adverse events were reported for 7 of 9 patients undergoing therapy, with two patients exhibiting cytokine release syndrome (CRS) of mild (Grade 1) to moderate (Grade 2) severity, respectively, that were manageable with concomitant IL-6 therapy. No neurotoxicity or dose-limiting toxicities were reported. Four patients died from their disease, with none considered related to MDG1011, and none at DL3. Two out of 9 patients showed early response on treatment at week 4. Of these, one AML patient treated with DL1 showed complete remission at week four, but disease progression was detected at week twelve. One patient with multilineage MDS/MPN treated with DL3 remained stable and did not show any progression to secondary AML throughout the 12-month study. MDG1011 TCR-T cells were present in PB of 6 of 8 patients within the first four weeks, with detection still possible in the MDS/MPN patient at twelve months. Four patients (3 AML, 1 MM) displayed decreased PRAME levels in BM, while one patient (MM) showed slightly elevated expression at week four. The MDS/MPN patient showed PRAME levels below baseline in PB throughout the 12-month observation period. Application of MDG1011 was generally well tolerated by heavily pre-treated patients who received up to 5 M CD8-positive PRAME-specific TCR-T cells/kg body weight. Clinical observations were corroborated by persistence of MDG1011 cells in PB and reduction of PRAME levels in PB and/or BM. Original source: Medigene, website: http://www.medigene.de/, Copyright Medigene AG 2023., research and development; anticancer drugs; cell therapies; [...]

Medigene AG, an immuno-oncology company focusing on the development of differentiated TCR-T therapies for cancers, presents on 8 Nov 2022 new data on reproducible production of TCR-T cells from elderly haematologically-challenged patients with blood cancers at the Cell UK Conference taking place 7-8 Nov 2022 in London. The presentation can be found on Medigene´s website: https://www.medigene.com/technologies/abstracts. MDG1011 is an autologous TCR-T therapy specific for a peptide fragment of PRAME (PReferentially expressed Antigen in MElanoma), a tumour antigen presented on cancer cells by human leukocyte antigen HLA-A2. Generation of MDG1011 in the phase I dose escalation trial (NCT03503968) was complicated by numerous factors impacting the potential quality of T cells, including that patients suffered from blood cancers, were heavily pretreated, and were mostly elderly. Leukaemia blasts were detected at high levels in the blood of several patients during the leukapheresis process performed to obtain the starting patient-specific T cells for MDG1011 manufacture, which had the potential to hinder the production and the final purity of MDG1011 drug products. Despite this, a success rate of 92% was achieved in production of TCR-T cells for twelve of thirteen patients using a semi-automated modular manufacturing process. Assessment of immune reactivity demonstrated high antitumour activities for all final MDG1011 products, as potential markers of potency. Patients underwent leukapheresis and CD8-positive T cells were enriched and cryopreserved for use in generation of MDG1011 drug products. Following thawing and activation, the PRAME-specific T cell receptor was introduced into CD8-positive T cells via retroviral gene transfer. TCR-T cells were expanded and cryopreserved for later shipment to the clinical centres for thawing and application to the patients as a single infusion. The GMP processes of drug product manufacture and quality control, with subsequent immune assessments of thawed MDG1011 products demonstrated: Generation of highly-enriched CD8-positive TCR-T cells was successful, despite high variability in the patient leukapheresis starting materials, with no detection of residual blood cancer cells in final MDG1011 products; TCR-T cells expressing the PRAME-specific TCR were produced in the required numbers needed for a dose escalation phase I study of MDG1011; MDG1011 showed high viability through all steps of the process, including before and after cryopreservation; Poly-functional cytokine secretion and killing capacity for tumour cell lines was seen with all MDG1011 products upon antigen-specific stimulation in vitro directly after thawing; Diverse subsets of T cells were retained during the manufacturing process of MDG1011 products, including stem cell memory T cells, central memory T cells and other effector memory T cells. Overall, highly successful generation of MDG1011 was feasible for haematologically-challenged patients. The TCR-T cells displayed excellent viability after thawing and antigen-specific poly-functional cytokine secretion was observed for all MDG1011 products manufactured from such patients. Original source: Medigene, website: http://www.medigene.de/, Copyright Medigene AG 2022., research and development; anticancer drugs; cell therapies; [...]

Experts delineate the current trends and future perspectives in this evolving therapeutic field, underscoring its importance in treating hematological cancers BEIJING, Nov. 3, 2022 /PRNewswire/ -- Allogeneic hematopoietic stem cell [...]

2023 APR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators publish new report on Coronavirus - COVID-19. According to [...]

2023 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Research findings on Coronavirus - COVID-19 are discussed in a [...]

Medigene AG, an immuno-oncology company focusing on the development of T-cell-based cancer therapies, announces the publication of a new peer-reviewed publication in the journal Cancers showing that the chimeric PD1-41BB receptor augments antigen-specific activity of T cell receptor-modified T cells (TCR-T cells) while retaining a favourable safety profile. The data suggests that the PD1-41BB switch receptor is a promising tool to overcome PD-1/PD-L1 inhibition in the tumour microenvironment of solid cancer without the negative side-effects associated with the use of systemic PD-1/PD-L1 checkpoint inhibitor antibodies. The inhibitory PD-1/PD-L1 checkpoint axis is a negative influence on T cell efficacy, fitness and persistence. Systemic use of anti-checkpoint antibodies benefits clinical outcomes in some patients but is often associated with drug-related immunotoxicities. Medigene developed the PD1-41BB chimeric receptor, which is exclusively expressed in the therapeutically active TCR-T cells to switch inhibitory PD-1/PD-L1 interactions into positive signals that enhance antigen-specific TCR-T cell function. The publication describes how Medigene isolated the HLA-A2-restricted, PRAME-specific T cell receptor (TCR) 'TCR-4' from blood from healthy donors (tapping a non-tolerized T cell repertoire) and how TCR-T cells expressing TCR-4 and the PD1-41BB switch receptor show improved effector functions, a favourable safety profile in vitro, reject tumours in vivo and have a poly-cytokine profile upon antigen-specific activation. The Cancers publication is titled 'T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity' and has recently been published online: https://www.mdpi.com/2072-6694/14/8/1998. Original source: Medigene, website: http://www.medigene.de/, Copyright Medigene AG 2022., research and development; anticancer drugs; cell therapies; [...]

2022 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

DECODE's characterization of epitopes, T cell receptor (TCR) sequences and T cell phenotype provides new insights into the memory response to SARS-CoV-2 infection CAMBRIDGE, Mass. -- Repertoire Immune Medicines, announced [...]

2022 JUN 7 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

* Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa's unique technology and breakthrough antibody-based drugs. * Abexxa's focus is on the development of specific antibodies to intracellular [...]

2022 FEB 6 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

MIRAMAR, Fla., Feb 24, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model -- The Ii-Key vaccine elicits [...]

M2 EQUITYBITES-November 19, 2021-Repertoire Immune Medicines' DECODE Platform identifies characterization of CD8+ T Cell responses to SARS-CoV-2 (C)2021 M2 COMMUNICATIONS http://www.m2.com Disease company Repertoire Immune Medicines announced on Thursday the [...]

2021 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 SEP 5 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 JUN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 MAY 9 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 APR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 FEB 21 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

2021 FEB 8 (NewsRx) -- By a News Reporter-Staff News Editor at Proteomics Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

2021 JAN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- According to news reporting based on a preprint abstract, our [...]

PHILADELPHIA and OXFORD, United Kingdom, Feb 09, 2016 (GLOBE NEWSWIRE via COMTEX) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, [...]

Researchers detail in 'HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro,' new data in breast cancer. [...]

Researchers detail in 'Association of human leukocyte antigen and esophageal cancer in North of Iran,' new data in esophageal cancer. 'Several risk factors including environmental factor, Genetic and nutritional deficiencies [...]